Roche has made the difficult decision not to move forward with a new clinical trial for rugonersen and has initiated the search for an external partner to take over the development. The conclusion of this trial undoubtedly brings feelings of […]
Read more
The International Angelman Syndrome Alliance (ASA) and the Angelman Syndrome Foundation (ASF) announced a newly formed joint initiative: the Global Community Advisory Board (CAB). They will work together to represent the Angelman community as a unified voice when engaging with […]
Read more
On July 23, 2020, Ovid Therapeutics announced a research collaboration with UCONN Health and Stormy Chamberlain, PhD. This exciting work began as an innovative idea funded by the Angelman Syndrome Foundation. Short hairpin RNA (shRNAs) work like ASOs, but can be […]
Read more
A new network platform, Linking Angelman and Dup15q Data for Expanded Research (LADDER), will offer caregivers access to information about a larger population of patients living with Angelman or Dup15 syndromes to better inform their decisions regarding treatments and interventions. […]
Read more
See the following announcement from May 16, 2019. Also, see a Q&A on this collaboration for more details. Dear Angelman Syndrome Community, We, Roche, Biogen and Ionis, are amongst several companies working towards finding potential treatments for Angelman Syndrome (AS). […]
Read more
On December 6, 2018, Ovid Therapeutics announced plans to move ahead with a single, pivotal Phase 3 trial of once-daily dosing of OV101 in pediatric patients with Angelman syndrome. This is based on its End-of-Phase 2 Meeting with the U.S. […]
Read more Additional Data and Analyses from the Phase 2 STARS Clinical Trial with OV101 Ovid Therapeutics Presents Additional Data and Analyses from the Phase 2 STARS Clinical Trial with OV101 for the Treatment of Angelman Syndrome at the 65th AACAP Annual Meeting […]
Read more— OV101 achieved primary endpoint of safety and tolerability — — Robust and statistically significant improvement (p=0.0006) in the first prespecified efficacy endpoint(CGI-I) observed at 12 weeks of treatment in once-daily dose group compared to placebo — — STARS data […]
Read more